GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 229 filers reported holding GENMAB A/S in Q3 2023. The put-call ratio across all filers is 1.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $603,682 | -0.4% | 17,116 | +7.4% | 0.03% | +3.0% |
| Q2 2023 | $605,842 | +1.2% | 15,939 | +0.6% | 0.03% | -5.7% |
| Q1 2023 | $598,535 | -15.5% | 15,851 | -5.1% | 0.04% | -22.2% |
| Q4 2022 | $708,000 | +34.9% | 16,706 | +2.3% | 0.04% | +21.6% |
| Q3 2022 | $525,000 | +33.6% | 16,328 | +35.2% | 0.04% | +37.0% |
| Q2 2022 | $393,000 | -29.6% | 12,075 | -21.7% | 0.03% | -15.6% |
| Q1 2022 | $558,000 | -1.9% | 15,414 | +7.1% | 0.03% | 0.0% |
| Q4 2021 | $569,000 | -7.2% | 14,389 | +2.6% | 0.03% | -15.8% |
| Q3 2021 | $613,000 | +15.9% | 14,031 | +8.3% | 0.04% | +18.8% |
| Q2 2021 | $529,000 | +21.9% | 12,958 | -2.0% | 0.03% | -3.0% |
| Q1 2021 | $434,000 | -22.8% | 13,228 | -4.2% | 0.03% | -13.2% |
| Q4 2020 | $562,000 | +4.1% | 13,804 | -6.4% | 0.04% | -20.8% |
| Q3 2020 | $540,000 | +39.5% | 14,753 | +29.3% | 0.05% | +29.7% |
| Q2 2020 | $387,000 | +72.0% | 11,413 | +13.1% | 0.04% | +68.2% |
| Q4 2019 | $225,000 | – | 10,092 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |